Dendritic Cell Vaccination for Glioma Patients
Author Information
Author(s): Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R
Primary Institution: Niigata University
Hypothesis
Can vaccination with dendritic cells pulsed with tumor lysate elicit immune responses in patients with recurrent glioma?
Conclusion
The study demonstrated that dendritic cell therapy is safe and can elicit immune responses in patients with malignant glioma.
Supporting Evidence
- Dendritic cell therapy was shown to activate systemic immune responses in some patients.
- Two patients exhibited minor responses to the treatment as evaluated by MRI.
- Significant increases in CD56-positive cells were observed after vaccination.
- Intratumoral T-cell infiltration was detected in patients who underwent reoperation after vaccination.
Takeaway
Doctors gave 10 patients with brain tumors a special vaccine made from their own immune cells to help fight the cancer, and it seemed to work safely.
Methodology
Patients received dendritic cells pulsed with autologous tumor lysate every 3 weeks for up to 10 vaccinations, and their immune responses were monitored.
Potential Biases
Potential selection bias due to the small number of patients and lack of randomization.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
10 patients (6 women, 4 men) aged 20 to 69 years, with a median age of 46.1 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website